Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0000875320-24-000101 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | 2024-02-23 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | F - Tax | $431.79 | -1,654 | 16.9K | -9% | -$714.2K | |
| 2024-02-27 | 2024-02-26 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $425.70 | -883 | 16.0K | -5% | -$375.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | F | D | 1,654 | $431.79 | 16,855 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-26 | S | D | 883 | $425.70 | 15,972 | D | — | — |